Posted in | News | Nanomedicine | Nanotoxicology

Nanoscale Whole Genome Imaging Technology to be used in Genetic Analysis System Using

Agilent Technologies Inc. and BioNanomatrix Inc. announced that they have entered into a collaboration to develop a new genetic analysis system combining the two companies’ technologies. BioNanomatrix, which develops breakthrough nanoscale whole genome imaging and analytic platforms, will apply its innovative nanoscale single molecule imaging technology to develop consumable chips and reagents, while Agilent will develop the measurement instrumentation platform for the system.

“This collaboration with Agilent provides us with the opportunity to join forces with a global life sciences leader to accelerate the development of our unique nanoscale whole genome imaging technology,” said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix. “We now have a partner with strong life sciences expertise and capabilities committed to working with us to develop key life-sciences applications, such as assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing.”

BioNanomatrix is developing pioneering technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format. The company’s patented analytic platform based on this technology has the potential to provide rapid, comprehensive and cost-effective ultra-high resolution analyses of DNA. The two companies intend to collaborate closely in the development of an integrated system and applications.

“BioNanomatrix’s unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life sciences research and clinical medicine,” said Nick Roelofs, vice president and general manager of the Life Sciences Solutions Unit at Agilent. “We are committed to continuing our leadership in developing important new technologies and solutions for our customers, and we look forward to collaborating with the BioNanomatrix team to enable these powerful new capabilities to reach the marketplace.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.